The optimal prophylactic strategy for cytomegalovirus (CMV) disease after allogeneic hematopoietic stem cell transplantation has not yet been established. The aim of this study was to analyze our single-center experience with a uniform protocol of CMV antigenemia-guided pre-emptive treatment with ganciclovir (GCV) after allografting. Fifty-two consecutive adult patients, 48 of them transplanted from HLA-identical matched related donors were included. T cell-depleted marrow or peripheral blood were used in 21 cases. After engraftment, weekly blood samples were tested for CMV pp65 antigenemia and viremia (conventional cultures) until day +100. GCV was started if CMV antigenemia and/or CMV viremia were detected. CMV infection (CMV-I) was found in 19 patients (37%). Seven patients suffered from CMV disease (CMV-D), three colitis and four pneumonias. There was one death directly related to CMV-D and three further cases died from refractory GVHD with CMV-D. Only one patient developed CMV pneumonia without any previous positive antigenemia and/or viremia. Multivariate analysis identified grades II-IV acute GVHD (P = 0.02) and peripheral blood stem cell transplantation (P = 0.03) to be risk factors for developing CMV-I. In conclusion, this monitoring protocol allowed early treatment of CMV-I without progression to CMV-D. Pre-emptive therapy had the additional advantage of avoiding GCV administration in most of our allograft recipients. Keywords: CMV infection; antigenemia; BMT Cytomegalovirus (CMV) infection (CMV-I) remains a frequent cause of serious morbidity after allogeneic stem cell transplantation despite the introduction of ganciclovir (GCV). The systematic use of GCV following engraftment is effective in preventing infection and disease by CMV. However, prophylactic use of GCV remains controversial due to its toxicity and the indiscriminate treatment of many patients who would not develop CMV-I or CMV-D. avoid overtreating 30-65% of patients who will not develop CMV-I, sensitive detection methods have been developed to identify CMV reactivation at an early stage, thereby allowing for early (pre-emptive) treatment of the infection before the onset of disease.
avoid overtreating 30-65% of patients who will not develop CMV-I, sensitive detection methods have been developed to identify CMV reactivation at an early stage, thereby allowing for early (pre-emptive) treatment of the infection before the onset of disease. 1 These methods include direct detection of CMV pp65 antigen (antigenemia) in peripheral blood leukocytes (PBL) 3 and detection of CMV DNA by the polymerase chain reaction in PBL, plasma or serum. 4 Based on encouraging early reports with the use of antigenemia, 1 we designed a uniform protocol of CMV antigenemia-guided pre-emptive treatment with GCV used in all our allografted adults since January 1993. It was our hypothesis that the CMV antigenemia assay could be used to initiate GCV treatment in patients with CMV-I early enough to prevent progression to overt CMV-D, thereby limiting the use of GCV and thus preventing GCV-related neutropenia and its complications.
Patients and methods
Sixty-four consecutive adults received an allograft in our Division between January 1993 and October 1997. Twelve patients were considered non-evaluable for the development of CMV-I and CMV-D due to early death (within 30 days after transplant) (n = 8) or because the patient was previously untransfused and both the donor and recipient were CMV seronegative (n = 4). Detailed characteristics of the remaining 52 evaluable patients are shown in Table 1 . The median age was 42 years (range 18-58), and only four donor/recipient pairs were seronegative for CMV; these latter four patients had received prior chemotherapy at their referring institutions and were transfused with unscreened and unfiltered blood products, and we thus considered them at risk for CMV reactivation despite pre-transplant negative serology. Most patients were transplanted for leukemia, and 48/52 had an HLA-identical sibling donor. The stem cell source was bone marrow (BMT) in 32 cases and peripheral blood stem cells (PBSCT) in 20. Partial T cell depletion (TCD) of the graft (Ͻ0.5 × 10 6 CD3 + cells/kg in all cases) was performed in 21 cases (13 BMT and eight PBSCT), and eight of these patients received CMV prophylaxis with high-dose acyclovir post transplant. Twelve patients developed acute GVHD grade I and 24 grades II-IV (15 grades III-IV). All evaluable patients were followed until death or for at least 100 days post transplant in order to monitor for early CMV-I and disease. CMV-I was defined as the presence of a single pp65 antigen-positive cell or a positive viremia in peripheral blood. CMV-D was defined as the demonstration of CMV in biopsy specimens from visceral sites by culture and/or histology or by a positive culture or positive shell-vial direct fluorescence antibody stain of BAL samples in the presence of new or changing pulmonary infiltrates. CMV-associated disease was defined as low-grade fever, generalized malaise and pancytopenia which resolved following GCV treatment.
Antigenemia and viremia tests
After engraftment (WBC Ͼ1 × 10 9 /l), weekly heparinized blood samples were tested in all patients for CMV pp65-antigenemia and viremia until day +100, and thereafter only when clinically indicated. Pre-emptive GCV was started only if CMV antigenemia and/or viremia was detected, at a dose of 5 mg/kg i.v. every 12 h for 7 days followed by 5 mg/kg daily Monday to Friday for 21 days. In case of relapse a second course was given, but this occurred in only one case. CMV antigenemia testing was performed in duplicate as described previously. 5 Briefly, an indirect immunofluorescence technique was used to detect the presence of any pp65-positive cells. The polymorphonuclear leukocyte fraction was separated from 10 ml of heparinized blood by sedimentation in a 6% dextran solution. 2 × 10 5 leukocytes were cytocentrifuged onto glass slides, fixed with 5% formaldehyde for 10 min and air dried. For staining, a pool of monoclonal antibodies to the CMV pp65-69 polypeptide was used (95/12 Monofluo Kit CMV; Sanofi Diagnostics Pasteur, Barcelona, Spain). After 30 min of incubation the slides were washed twice with PBS and then stained with fluorescein-conjugated mouse anti-IgG sheep antibodies (Monofluo Kit CMV). Slides were washed again with PBS and mounted. Reading was done under a fluorescence microscope to search for fluorescence-positive cells, and the presence of a single positive cell in both slides was considered a positive result. The number of CMV-positive cells was expressed per 2 × 10 5 leukocytes studied in a semiquantitative manner. For conventional culture (viremia) blood was inoculated into MRC5 cells and maintained for at least 4 weeks, as previously described in detail. 6 
Statistical methods
The closing date for analysis was 31 December 1997. CMV-I rates were estimated by the Kaplan-Meier method until day +100. Actuarial curves were compared by means of the log-rank test. Cox proportional hazards models were used to analyze risk factors for CMV-I with a significance level of P р 0.05.
Results
The results are summarized in Table 2 . Of the 52 evaluable patients, 19 (37%; 95% CI 23-49%) developed CMV-I post transplant. Specifically, 11 were positive both for antigenemia and viremia; one of these patients had concurrent CMV-D and two developed CMV-D 4 and 5 days from the first positive antigenemia. Three patients developed only antigenemia, with one being diagnosed with CMV colitis simultaneously with the first positive result. Four developed only a positive viremia without a positive antigenemia; two of these patients developed CMV pneumonia 10 and 14 days from the first positive viremia, while the other two suffered CMV-associated syndrome. One further patient underwent bronchoscopy for a lobar pneumonia and was found to have a BAL culture positive for CMV, and he Table 2 Results
Patients evaluable for CMV-I/D 52 GVHD Grade I  12  Grade II-IV (III-IV) 24 ( There were four cases of interstitial pneumonia and three colitis. Additionally, two patients developed CMV-associated syndrome, defined as low-grade fever, generalized malaise and pancytopenia which resolved following GCV treatment, which is considered a form of CMV-I rather than disease. 7 One of the three cases of colitis and one pneumonia presented with gastrointestinal and respiratory symptoms simultaneously with the first positive antigenemia, while two cases of colitis were preceded by a positive antigenemia by 3 and 4 days. Two pneumonias had their first positive viremia (negative antigenemia) 10 and 14 days before the onset of symptoms, when the results of conventional CMV cultures were not yet available, and one pneumonia had no previous or concurrent positive blood samples. All four patients with pneumonia died, but in three of them the primary cause of death was refractory grade IV acute GVHD with pulmonary aspergillosis (n = 2) and progressive lymphoma (n = 1), and in only one case was CMV-D the primary cause of death, although this patient also had toxoplasma encephalitis at autopsy. All cases of colitis were cured with GCV. Of these seven cases of CMV-D, five did not receive GCV before the onset of symptoms (two due to a first simultaneous positive antigenemia, two due to a previous positive viremia but with results after the onset of symptoms and one due to lack of any previous or concurrent positive blood samples) and two colitis had started pre-emptive GCV only 2 days before the onset of disease for a positive antigenemia.
Conversely, 12 cases who developed a positive antigenemia/viremia without signs of CMV-D (including the two with the CMV-associated syndrome) did not progress to CMV-D following GCV treatment.
To determine if any known clinical factors were predictive for the development of CMV-I or disease in our series, we analyzed the impact of five factors (Table 3 ). In the univariate analysis only the source of the stem cell allograft had statistical significance (PBSCT 55% vs BMT 25%, P = 0.02), but in multivariate analysis both the source of the graft (P = 0.03) and the development of grades II-IV acute GVHD (0-I 25% vs II-IV 50%, P = 0.02) increased the risk of developing CMV-I. To analyse the possible impact of viral load, expressed as the number of pp65-positive nuclei per 2 × 10 5 cells, on the development of CMV disease, we compared the incidence of CMV-D in the 14 patients with positive antigenemia; the incidence in patients with Ͻ3, 3-9, 9-19 and Ͼ19 positive cells was 1/4, 1/3, 0/2 and 2/5, respectively. The risk of developing disease was not significant when comparing р9 vs Ͼ9 positive nuclei (2/7 vs 2/7) or р19 vs Ͼ19 positive cells (2/9 vs 2/5) (P = 0.26 and P = 0.15, respectively, by Fisher's exact t-test).
Discussion
Previous pre-emptive treatment of CMV-I was based on positive conventional or shell vial CMV blood cultures (viremia), with 29-32% of patients developing CMV-D without preceding CMV viremia. 1, 8, 9 The more aggressive approach of administering GCV at engraftment 2 is effective in preventing CMV-D before day 100 after transplantation in seropositive patients (ie incidence of disease 0-10%), but it has the disadvantages of treating 100% of patients, resulting in 30-65% of patients receiving GCV unnecessarily. 1 Thus, in the past years more sensitive methods for early detection of CMV-I have been pursued.
The CMV antigenemia was initially described by Van der Bij and colleagues 3 and has been studied by various groups in this setting. Table 4 summarizes the results from Table 4 Previous studies using antigenemia-based monitoring after SCT previous studies. Our incidences of CMV-I and CMV-D compare favorably with other series that have used a similar approach of CMV monitoring and pre-emptive treatment. 7, 10 As expected, when GCV prophylaxis is used the rates of CMV viremia and antigemia post transplant appear to be lower, 19 and 23%, respectively, in the 61 patients studied by the MD Anderson transplant group. 11 In the largest previous report of patients not receiving GCV prophylaxis, Bacigalupo et al 7 had a rate of CMV reactivation of 43%, with 21% of 134 allografts developing CMV pneumonia. Although these rates are higher than ours, the patient populations and methodology of the two studies may have been different, making direct comparisons of little use.
Recently, results of the first randomized trial comparing pp65 antigenemia-guided early treatment vs ganciclovir at engraftment have been published. 10 The rate of positive antigenemia before day 100 was 79% in the 90 evaluable patients assigned to the antigenemia group, a higher rate than reported by other authors (see Table 4 ). In this study, however, 51% of the BMT were from mismatched related or unrelated donors, who have a much higher incidence of CMV-I. 12 Additionally, of the 112 patients assigned to receive prophylactic GCV 41% developed antigenemia, further emphasizing the high-risk population studied. The antigenemia group had a 14% incidence of CMV-D before day 100, vs 2.7% in the GCV group. However, there were no significant differences in the incidence of CMV-D by day 180 and in overall survival between groups due to the higher rates of late CMV-D (beyond day 100) and ganciclovir-related adverse events in the latter group. Thus, there appears to be no clear-cut advantage of the systematic use of GCV post-engraftment over the antigenemia-based preemptive treatment. It is encouraging that in this high-risk setting prophylactic GCV at engraftment and antigenemiabased pre-emptive treatment proved of similar efficacy. It must be emphasized, however, that CMV disease may develop without a previous positive antigenemia and/or viremia, or the first positive result may precede the onset of disease by only a few days, even with routine weekly sampling. In our experience, this occurred in all seven cases of CMV-D, and in previous reports 15-30% of patients at risk developed CMV-D, emphasizing the need for continued research efforts in prophylaxis 2 and early diagnosis 4, 21 of CMV infection in allogeneic SCT recipients. In our multivariate analysis, the development of moderate to severe acute GVHD and the source of the stem cell transplant were associated with the development of CMV-I (Table 3) . Although acute GVHD is a well-known risk factor for CMV-I, 7,10 PBSCT has not been reported to increase these infections with respect to BMT. 16 Since CMV is transferred through leukocytes, a possible explanation for this observation could be the higher viral burden in PBSC than in bone marrow. In vivo post transplant, the viral burden in the host appears to be predictive for the development of CMV-D, 7, 10, 22 but it is unproven that the quantity of virus infused with the graft plays a role or whether reactivation of latent virus is an independent phenomenon. However, due to the small patient groups our results require confirmation in larger series of patients.
An issue not analyzed in our study is the occurrence of late (Ͼ100 days post-transplant) CMV-I and disease, a period when patients are usually not monitored routinely at most institutions. Recently, late CMV infections have emerged as a significant problem in several studies, 10, [13] [14] [15] and the main risk factors appear to be unrelated or mismatched donors, chronic GVHD, T cell-depleted allografts and lack of recovery of a CMV-specific cytotoxic T lymphocyte response. 14 In our study, three patients died from idiopathic bilateral pneumonia 6-10 months post transplant at their referring institutions, and CMV may have been involved in these infections. Thus, it may be worthwhile to monitor high-risk patients weekly for the first 180 days post transplant and even thereafter in selected cases to better define the real magnitude of late CMV infections in different settings and design more adequate pre-emptive strategies.
In conclusion, in our experience weekly testing for CMV antigenemia and viremia post engraftment and early treatment with GCV proved effective in achieving a low rate of early CMV disease, making this infection a relatively infrequent cause of serious morbidity-mortality in allogeneic stem cell transplant recipients. An additional benefit of such pre-emptive approaches is the substantial number of patients who never receive GCV post transplant (67% in our series), reducing the problems associated with its use in this patient population.
